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Summary
The hepatitis C virus (HCV) is a major etiologic agent for severe liver diseases (e.g. cirrhosis,
fibrosis and hepatocellular carcinoma). Approximately 140 million people have chronic HCV
infections and about 500 000 die yearly from HCV-related liver pathologies. To date, there is no
licensed vaccine available to prevent HCV infection and production of a HCV vaccine remains a
major challenge. Here, we report the successful production of the HCV E1E2 heterodimer, an
important vaccine candidate, in an edible crop (lettuce, Lactuca sativa) using Agrobacterium-
mediated transient expression technology. The wild-type dimer (E1E2) and a variant without an
N-glycosylation site in the E2 polypeptide (E1E2ΔN6) were expressed, and appropriate
N-glycosylation pattern and functionality of the E1E2 dimers were demonstrated. The humoral
immune response induced by the HCV proteins was investigated in mice following oral
administration of lettuce antigens with or without previous intramuscular prime with the
mammalian HEK293T cell-expressed HCV dimer. Immunization by oral feeding only resulted in
development of weak serum levels of anti-HCV IgM for both antigens; however, the E1E2ΔN6
proteins produced higher amounts of secretory IgA, suggesting improved immunogenic
properties of the N-glycosylation mutant. The mice group receiving the intramuscular injection
followed by two oral boosts with the lettuce E1E2 dimer developed a systemic but also a mucosal
immune response, as demonstrated by the presence of anti-HCV secretory IgA in faeces extracts.
In summary, our study demonstrates the feasibility of producing complex viral antigens in lettuce,
using plant transient expression technology, with great potential for future low-cost oral vaccine
development.
Introduction
Hepatitis C virus (HCV) is an enveloped, single-stranded, positive-
sensed RNA virus of the Flaviviridae family, causing severe liver
diseases, which usually progress to fibrosis, cirrhosis and ulti-
mately fatal hepatocellular carcinoma (Luo et al., 2014). Accord-
ing to the World Health Organization, approximately 140 million
people are HCV-infected worldwide, with 3–4 million new cases
occurring annually (WHO, 2016). The vast majority (80%) of
HCV-infected people live in low- and middle-income countries,
the highest prevalence of infection being reported in Africa and
the Middle East (Hajarizadeh et al., 2013). Innovative anti-HCV
therapies, including the new generation of interferon-free direct-
acting antivirals (DAAs), have recently become available and offer
the possibility to control the epidemic; however, the major
drawback of the novel therapeutics is their high cost. In addition,
not all HCV-infected patients can be fully cured and the
treatment’s side effects are not negligible (Wedemeyer et al.,
2014). Therefore, development of a prophylactic vaccine against
HCV remains a top medical priority, despite serious difficulties,
mainly associated with the high genetic diversity of this pathogen
(Cashman et al., 2014).
The HCV envelope proteins E1 and E2 are type I transmem-
brane glycoproteins which associate to generate a noncovalent
heterodimer, immediately after their processing from the HCV
polyprotein by signal peptidase cleavages (Lavie et al., 2007,
2015). The E1E2 dimer was shown to induce broad cross-
genotype neutralizing antibodies (nAbs) in chimpanzees and delay
the progression to a chronic Hepatitis C infection (Houghton,
2011). Moreover, nAbs were also detected in E1E2-immunized
human volunteers (Stamataki et al., 2011), suggesting that the
E1E2 dimer represents a promising candidate for future vaccine
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development. It has reached phase I clinical trials and proved to
display good safety and tolerance profiles, inducing strong
antibody and lymphoproliferative responses (Frey et al., 2010).
Interestingly, most of the nAbs are raised against the E2 domain
responsible for the interaction with the CD81 viral receptor (Flint
et al., 1999). In addition, the E1E2 heterodimer exhibits stronger
immunogenic properties than either of the two monomers
(Dunlop et al., 2015). However, the heavy N-linked glycosylation
of the envelope proteins was found to be involved in viral immune
evasion, by shielding potentially immunogenic epitopes on the
viral surface (Helle et al., 2010). Specifically, the E2 N-glycans
were shown to modulate the neutralizing activity of anti-HCV
antibodies (Helle et al., 2007). Most of the recombinant E1E2
dimers used in these studies were produced in mammalian cell
culture. However, expression in this system is difficult to scale up,
requiring for example strict sterile conditions and high costs for
GMP, and very costly for commercial use; therefore, cheaper
strategies for E1E2 dimer production are urgently needed.
Plant production of biopharmaceuticals, including vaccine
antigens and antibodies, is a very attractive alternative production
system as plants offer a number of advantages over more
traditional systems (Bock, 2014, 2015; Chan and Daniell, 2015;
Chan et al., 2016; Clarke and Daniell, 2011; Daniell et al., 2015).
Plant hosts permit the recombinant proteins to be cost-effectively
produced at large scale (due to the very low production costs of
plant biomass and the easily scalable production levels, Stoger
et al., 2014; Ma et al., 2015). Also, the risk of contamination
from potential human pathogens is very low when using plant-
based production systems (Peyret and Lomonossoff, 2015;
Schillberg et al., 2013). A recent critical review on the cost-
effectiveness of different vaccine and antibody production
systems has shown that plant-based production systems not only
offer the low-cost advantage, but also several other advantages,
such as high safety, production quality and protein folding
accuracy when compared with other systems, including mam-
malian cell cultures, transgenic livestock, yeast and bacterial
cultures (Zhang et al., 2017). A number of recent advancements
and successes in plant molecular farming, such as the ZMapp™
antibody against Ebola which saved two lives during the Ebola
outbreak, and the cold chain and virus-free oral booster polio
vaccine, have convincingly demonstrated the great potential of
plant-based production systems for biopharmaceuticals (Chan
et al., 2016; Hiatt et al., 2015). Furthermore, the cGMP manu-
facturing facility available at Fraunhofer USA Center (http://
www.fhcmb.org) permits clinical grade plant-based vaccines and
therapeutics to be produced in gram quantities.
Edible plants have additional advantages for the production of
therapeutic proteins and vaccines, by facilitating oral delivery,
they eliminate the need for expensive fermentation, purification,
cold storage, transportation and sterile delivery (Chan and
Daniell, 2015; Kwon and Daniell, 2015). Oral delivery of
recombinant plant-produced vaccines is a desirable means of
vaccination due to the simplicity and safety of administration. The
cost of downstream processing is usually about 80% of the
production cost for plant-made pharmaceuticals and vaccines
(Chan and Daniell, 2015; Posgai et al., 2017; Shahid and Daniell,
2016). Thus, edible crops offer unique cost advantages. Stability
of antigens at room temperature is also a highly desired property
of vaccines. Chan et al. (2016) have recently reported a cold
chain-independent and virus-free chloroplast-made booster vac-
cine to confer immunity against different poliovirus serotypes,
again confirming the great potential of oral vaccines made in
edible crops. However, as such examples are still scarce, more
research is clearly needed to advance the field of low-cost oral
vaccines produced in edible crops.
In this study, we sought to develop a production system for the
HCV E1E2 heterodimer in lettuce (Lactuca sativa), an edible crop
which has become a promising host for plant-made oral vaccines
and other biopharmaceuticals, using either stable chloroplast
transformation or transient expression of genes targeted to the
nucleus (Chan and Daniell, 2015). The wild-type (wt) E1E2
polypeptide and an E2 N-glycosylation mutant (E1E2ΔN6) were
successfully expressed in lettuce using Agrobacterium-mediated
transient expression. The E1E2 polypeptide was correctly pro-
cessed in plant cells and the N-glycosylation pattern was similar to
that of the E1E2 dimer produced in mammalian HEK cells
(Goffard et al., 2005). The antigenic properties of the recombi-
nant HCV proteins were analysed in mice using several immu-
nization strategies, consisting of oral administration of lettuce
with or without a previous intramuscular (im) prime using the HEK
cells-expressed HCV dimer. The results demonstrated an early
systemic immune response in the mice group receiving the im
injection followed by two oral boosts with the E1E2-expressing
lettuce. While immunization performed by oral feeding only
resulted in weak serum levels of anti-HCV IgM for both the E1E2
and the E1E2ΔN6 antigens, higher amounts of secretory (s) IgA
were detected in the latter case, indicating improved immuno-
genic properties of the E1E2 heterodimer in the absence of the
corresponding N-linked glycan. In this study, we provide the first
evidence that complex viral antigens, requiring host protease
processing, post-translational modifications and an appropriate
folding environment to facilitate noncovalent, functional dimer-
ization can be produced in plant cells, while preserving the
immunogenic properties of mammalian virus-derived proteins.
The data also highlight the role of particular N-linked oligosac-
charides attached to the E2 glycoprotein in the development of
the immune response against HCV. Our study demonstrates the
potential of molecular farming and of oral vaccines made in
edible crops for future low-cost vaccine development.
Results
HCV E1E2 and E1E2ΔN6 expression vectors and transient
expression of HCV E1E2 and E1E2ΔN6 antigens in
Lactuca sativa
In order to produce HCV E1E2 and E1E2ΔN6 antigens in an edible
crop, lettuce, for future oral HCV vaccine development, we
designed and constructed two plasmid vectors for expression of
the E1E2 and E1E2ΔN6 antigens in L. sativa cv Veronique
(Figure 1). We also constructed a control vector expressing GFP
as a reporter gene for protocol optimization and use as a positive
control throughout the study (Figure 1). The E1E2 and E1E2ΔN6-
encoding transgenes were inserted into the pEAQ versatile
transient expression vector developed by Sainsbury et al. (2009)
using the Gateway cloning technology (Life Technologies,
Carlsbad, USA). All three expression vectors were subsequently
transformed into Agrobacterium tumefaciens LBA4404 by elec-
troporation as described in the “Materials and Methods” section.
Next, we established a protocol for expression of recombinant
proteins in both Nicotiana benthamiana and lettuce using the
pEAQ-DEST1/GFP reporter gene-expressing vector, prior to the
production of HCV E1E2 and E1E2ΔN6 antigens in lettuce. We
optimized the protocol and the technical procedures using the
pEAQ-DEST1/GFP reporter gene expression vector (Figure 2a, b).
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To produce sufficient amount of E1E2 and E1E2ΔN6 antigens
required for animal immunogenicity assays, an in-house assem-
bled vacuum system was applied and HCV E1E2 antigen
accumulation 6 days after agroinfiltration (6 dpi) was evident
(Figure 2c) when compared with the wild-type control (Fig-
ure 2d). Different operating parameters, such as the power of
pressure (bar), and the duration and number of infiltration rounds
were investigated to increase the efficiency of the procedure.
Various trials have led to the conclusion that vacuum pressure is a
crucial parameter for successful infiltration, and this was estab-
lished at 0.07 bar for lettuce.
Quantitative analysis of E1E2 and E1E2ΔN6 mRNA
expression in lettuce
The HCV E1E2 and E1E2ΔN6 transcript levels were analysed by
quantitative real-time reverse-transcription PCR (qRT-PCR) in
agroinfiltrated lettuce leaves harvested at different time intervals
(dpi). Expression of the reference genes ACT and EIF2A was used
to normalize the values obtained using the DDCq method. The
transgene-derived transcripts were readily detectable in Agrobac-
terium-infiltrated lettuce at day 6 postinfiltration (dpi) and further
increased at 8 dpi, when the highest expression level was reached
as shown in Table 1. A considerable amount of RNA transcripts
was still detected at 14 dpi (Table 1).
Expression of the HCV E1E2 heterodimer in HEK cells and
purification
As a mammalian reference system for the plant-produced E1E2
heterodimer, the complex was also produced in transiently
transfected HEK293T cells (Figure 3a). The purification strategy
was based on the property of these N-glycosylated proteins to
bind to lectins with specific affinity for high-mannose N-linked
glycans, such as the Galanthus nivalis (GNA) lectin. Cell lysates
were subjected to GNA-Sepharose affinity chromatography
and the high-mannose proteins were eluted with methyl
a-D-mannopyranoside. The total protein concentration was
Figure 1 Schematic representation of HCVE1E2, HCVE1E2DN6 and GFP gene expression vectors. The E1E2 and E1E2DN6 encoding genes were
introduced into pEAQ-HT-DEST1 vector using Gateway cloning technology. RB/LB, right and left borders; 50UTR and 30UTR, 50 and 30 untranslated regions
derived from Cowpea mosaic virus (CPMV); 35S P, 35S promoter; 35S T, 35S terminator; Nos P, nopaline synthase promoter; Nos T nopaline synthase
terminator; P19, suppressor of gene silencing; nptII, neomycin phosphotransferase II gene conferring kanamycin resistance. GoI, gene of interest.
(a) (b)
(c) (d)
Figure 2 Transient expression of a GFP reporter
gene in N. benthamiana and of the HCV E1E2
antigens in lettuce. (a) Visualization of GFP
expression in N. benthamiana 6 days
postagroinfiltration (6 dpi) by UV microscopy (bar:
1 mm) and (b) light microscopy (bar 1 cm). (c)
Phenotype of HCV E1E2 expressing Lactuca sativa
at 5 dpi, compared with wild-type (wt) lettuce as
the control (d).
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determined before Western blot analysis of twofold serial
dilutions (Figure 3b). The concentration of the viral antigen was
estimated in a semi-quantitative manner, based on the affinity of
the anti-E2 antibodies (Abs) 3/11 described before (Flint et al.,
1999) and the sensitivity of the chemiluminescence-based detec-
tion method (pg range). The results indicated a total viral antigen
concentration of ~1.6 lg/mL and a purity of ~30% in concen-
trated samples.
Expression of the HCV E1E2 heterodimer in lettuce and
functional characterization
To examine polypeptide processing and determine the level of
expression of the E1E2 and E1E2ΔN6 viral heterodimers in plant
cells, the proteins extracted from lettuce leaves were subjected to
Westernblot analysiswith either E1- or E2-specificAbs.As shown in
Figure 4, the wild-type polypeptide and that of the N-glycosylation
mutant were produced at similar levels in lettuce. The E2 and E1
glycoproteins accumulated at the expected apparent molecular
weight of ~70 and ~30 kDa, respectively (Figure 4a, b) suggesting
correct processing of the E1E2 viral polypeptide by endogenous
processing proteases present in the plant cell, similar to that specific
to mammalian cells. The E2ΔN6 protein migrated slightly faster
than its wild-type counterpart, consistent with the loss of an N-
linked oligosaccharide (Figure 4a). Interestingly, both lettuce-
expressed E2 proteins displayed a slightly lower electrophoretic
mobility when compared to their mammalian cell-expressed
counterparts and appeared as broader bands. This migration
behaviour might reflect a more heterogeneous N-glycosylation or
addition of plant-specific O-glycans (Figure 4c). To investigate this
possibility, the protein extracts were subjected to endoglycosidase
H (Endo H) digestion, which cleaves within the chitobiose core of
the high-mannose glycans, but does not cleave complex N-glycans
attached toproteins (Figure 5). As expected, theHEKcell-produced
E2 proteinwas completely sensitive to EndoHdigestion (Figure 5a).
The lettuce-expressed E2 and E2ΔN6 polypeptides were also
sensitive to EndoH digestion, confirming their glycosylation (Fig-
ure 5, panels b and c). However, while EndoH digestion converted
the majority of the lettuce-expressed wild-type E2 to a protein of
similarmobility as the HEK cell-produced E2, there also appeared to
be a minor form that was treatment-resistant (Figure 5b, upper
band). This analysis suggests that some complex sugars may be
added during N-glycosylation processing in plant cells; however, a
large envelope protein pool contains high-mannose N-linked
glycan, as the protein expressed in mammalian cells. Alternatively,
this thin upper band could represent a small fraction of unpro-
cessed E1-E2 polypeptide. The slight reduction in the E2 polypep-
tide after the EndoH digestion of the E1E2ΔN6 lettuce extract is
most likely due to precipitation of a fraction of this protein, under
the harsh denaturation conditions requested for enzymatic cleav-
age (Figure 5c).
HCV infection critically dependsonE1E2binding to thehost cell’s
CD81 receptor. The highly conserved CD81-binding regions,
localized in the E2 protein, are the major target of a plethora of
nAbs. CD81-E2 interaction indicates exposure of the binding
domains within a correctly folded E2 protein. To investigate the
formation of the E1E2 heterodimer and the folding state of E2, we
performed a pull-down assay using as bait a recombinant form of
the CD81-LEL (large external loop) which forms the CD81 interac-
tion domainwith theHCV E2 protein. Lettuce proteins pulled down
by CD81-LEL were detected by Western blotting. As shown in
Figure 6, both E1 and E2 were identified in the pulled-down
samples derived from mammalian (Figure 6a) or plant cells
(Figure 6b). This suggests native folding of the CD81-binding
domainof E2, aswell as formationof a functional E1E2heterodimer
in plant cells, as E1 does not directly interact with CD81.
Immunogenicity of lettuce-derived HCV antigens
Todetermine the immunogenicity of theHCVantigens expressed in
transgenic lettuce, the experimental design included several
strategies. In addition to the control group, two groups of mice
were fedwith either E1E2- or E1E2ΔN6-expressing lettuce and two
groups of mice were first primed by intramuscular injection with
E1E2 purified from HEK293T cells, followed by oral or parenteral
boosting with E1E2-lettuce and HEK293T-derived E1E2, respec-
tively (Table 2). It is important to note that both oral and parenteral
immunizations were performed in the absence of adjuvants, to
have a clear evaluation of any antigen-specific immune response.
The kinetics of the anti-HCV IgM, IgG, IgAAbs accumulation in sera
and secretory (s) IgA in faeces wasmonitored before immunization
(day 0) and on days 14, 28 and 42.
Anti-HCV IgM Abs were detected in all mice sera from the
groups which received the intramuscular injection (Table 2,
Table 1 HCV E1E2DN6 gene expression in Lactuca sativa cv.
Veronique, measured by qRT-PCR
Sample (lettuce) dpi
Relative normalized
expression (fold change) P-value
0 1.00
6 38.58 0.000756
8 59.70 0.002639
14 16.95 0.000033
dpi, days postinfiltration.
Figure 3 Expression of the HCV E1E2-encoding gene in mammalian cells. (a) Lysates of control (lane 1) or E1E2-expressing HEK-293T cells (lane 2) were
subjected to Western blotting followed by sequential detection with anti-E2 Abs 3/11 and anti-E1 Abs A4. (b) The GNA-Sepharose purified E1E2
heterodimer (lane 1) was twofold serially diluted (lanes 2-10), followed by detection of the E2 polypeptide by Western blotting using the anti-E2 Abs 3/11.
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groups 1 and 4), indicating the development of a primary immune
response (Figure 7). The two groups of mice having received
either the E1E2ΔN6 or the E1E2 antigen via the oral route only
developed HCV-specific IgM reactivity sporadically and at low
level, starting from day 28 (Table 2, groups 2 and 3 and Figure 7).
None of these mice developed an anti-HCV IgG response during
the time frame investigated. The development of anti-HCV IgG
Abs was evidenced on day 28 in all mice immunized by injection
only (Table 2, group 4) and on day 42 in two of five mice orally
boosted with E1E2-expressing lettuce (Table 2, group 1) (Fig-
ure 8).
Anti-HCV IgA Abs were not detectable in sera of either group
of mice taken into the study (data not shown). By contrast,
HCV-specific sIgA Abs were detected in faeces extracts of the
group of mice orally immunized with E1E2ΔN6-expressing
lettuce (Table 2, group 2), but not in the group fed with E1E2
lettuce (Table 2, group 3). Anti-HCV secretory IgA was also
detected in faeces extracts in the mice groups primed by
intramuscular injection followed by oral or parenteral boosting
(Table 2, groups 1 and 4, respectively). The highest relative
concentration of anti-HCV sIgA was detected in mice orally
immunized with E1E2ΔN6-expressing lettuce on day 28, which
declined by day 42 (Figure 9, group 2). Interestingly, a compar-
ison between the mice groups primed by intramuscular injection
indicated that the relative concentration of anti-HCV sIgA
measured on days 14 and 28 was considerably higher in the
group boosted by oral feeding than in the group receiving the
intramuscular injection (Figure 9, groups 1 and 4).
Discussion
HCV vaccine development has turned out to be very challenging
because of the high diversity of the HCV genome and the
frequent mutations occurring during viral replication. These
difficulties are also associated with restricted humoral and cell-
mediated responses against HCV infection, low delivery of
Figure 4 Expression of HCV E1E2 and E1E2ΔN6-encoding transgenes in lettuce. Protein extracts in Lactuca sativa control leaves (lane 1), or leaves
expressing either the E1E2 (lane 2) or the E1E2ΔN6 heterodimer (lane 3) were subjected to immunoblotting and detection with anti-E2 Abs 3/11 (a) or anti-
E1A4 Abs (b). (c) Analysis as in (a), except that HEK293T cell lysates expressing the E1E2 (lane 2) or the E1E2ΔN6 heterodimer (lane 4) were also included, in
addition to control lettuce leaf extract (lane 1), and plant extracts containing the E1E2 (lane 3) or the E1E2ΔN6 heterodimer (lane 5).
Figure 5 N-glycosylation of HCV E1E2 and
E1E2ΔN6 produced in lettuce. Protein extracts
from E1E2-expressing HEK293T cells (a) and
Lactuca sativa leaves expressing E1E2 (b) or
E1E2DN6 (c) were treated with EndoH (+) or
maintained untreated () before Western blot
analysis and detection with anti-E2 Abs 3/11. The
glycosylated (gp) and nonglycosylated (p) E2
proteins are shown.
Figure 6 CD81 binding of lettuce-produced
HCV antigens. Protein extracts (input) from
HEK293T cells expressing the E1E2 dimer as
control (a) and Lactuca sativa Veronique leaves
expressing the E1E2 or E1E2DN6 dimers (b) were
reacted with GST-fused CD81-LEL adsorbed onto
glutathione–Sepharose beads. Lysates and CD81-
bound proteins were analysed by Western blotting
and sequentially detected with anti-E2 3/11 and
anti-E1A4 Abs.
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potentially protective viral epitopes and poor efficiency of the
adjuvants used in different immunization protocols (Garcia et al.,
2014). A unique feature of HCV infection is the late onset of
adaptive immune responses after infection. Production of HCV-
specific T cells appears within 2–5 weeks and seroconversion
occurs approximately 6–8 weeks after infection following the
initial T-cell response (Cooper et al., 1999; Missale et al., 1996).
It is well recognized that a strong and broad cytotoxic T
lymphocyte (CTL) response is important for HCV clearance
(Latimer et al., 2014). An effective preventive vaccine should be
able to induce strong neutralizing antibodies in addition to a
powerful cellular immune response to provide the best long-
term mechanisms for controlling HCV infection (Ippolito et al.,
2015). Currently, only a few potential HCV vaccines, consisting
of recombinant proteins, synthetic peptides, modified vaccinia
virus-based vaccines and DNA-based vaccines have progressed
to clinical trials, with the E1E2 complex being one of the most
promising candidate vaccines (Torresi et al., 2011; Wong et al.,
2014).
In the current study, we investigated for the first time the
potential of the HCV E1E2 heterodimer as an oral vaccine. Oral
vaccines are attractive due to their ability to elicit humoral and
cellular immunity via both the mucosal and the systemic
immune systems and the potential to eliminate undesired pain
and needle-associated risks from injections which often result in
low acceptance (Neutra and Kozlowski, 2006). However, oral
delivery is still a challenging immunization route, plagued not
only by the possibility of antigen degradation in the gastroin-
testinal tract (Lugade et al., 2010; Silin et al., 2007) but also by
the lack of efficient oral priming approaches and the risk of
inducing tolerance in the absence of host immune system
priming (Chan and Daniell, 2015; Kwon et al., 2013; Mason
et al., 2008).
Here, we have demonstrated that the full-length HCV E1-E2
polypeptide is efficiently processed by plant-specific processing
proteases resulting in release of mature E1 and E2 proteins. In
mammalian cells, these heavily glycosylated proteins undergo a
slow and complicated folding process involving acquisition of
Table 2 Total antibody positivity rate after different immunization strategies
Group No. mice
Vaccine and administration
Anti-HCV Abs
Days post-prime
Prime 2xboost 0 14 28 42
Serum IgM 0/5 0/5 0/5 0/5
0 5 Serum IgG 0/5 0/5 0/5 0/5
Faeces IgA 0/5 0/5 0/5 0/5
im Feeding Serum IgM 0/5 5/5 5/5 5/5
1 5 HEK293T-E1E2 Lettuce E1E2 Serum IgG 0/5 0/5 0/5 4/5
Faeces IgA 0/5 4/5 4/5 4/5
Feeding Serum IgM 0/7 0/7 1/7 2/7
2 7 Lettuce-E1E2ΔN6 Serum IgG 0/7 0/7 0/7 0/7
Faeces IgA 0/7 3/7 3/7 3/7
Feeding Serum IgM 0/5 0/5 1/5 1/5
3 5 Lettuce-E1E2 Serum IgG 0/5 0/5 0/5 0/5
Faeces IgA 0/5 0/5 0/5 0/5
4 5 im im Serum IgM 0/5 ND 5/5 5/5
HEK293T-E1E2 HEK293T-E1E2 Serum IgG 0/5 ND 5/5 5/5
Faeces IgA ND ND 5/5 5/5
Im, intramuscular; ND, not determined; bold text, antigen specific reactivity
Figure 7 IgM endpoint titres in sera of immunized mice. 1 – intramuscular prime with E1E2 purified from HEK293T cells, followed by two oral boosts with
lettuce-E1E2; 2 – three oral administrations of lettuce-E1E2ΔN6; 3 – three oral administrations of lettuce-E1E2; 4 – two intramuscular administrations of
E1E2 purified from HEK293T cells; endpoint titres were calculated based on a 4-parameter logistic regression curve fitted to a pool of immune sera, as the
reciprocal sample dilution that would result in three times baseline + standard error as derived from the internal standard curve by multiplication.
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intramolecular disulphide bridges and noncovalent dimerization.
This maturation pathway is strictly dependent on host factors,
including molecular chaperones and specific enzymes (Krey
et al., 2010). The ability of the lettuce-expressed E1E2 dimer to
bind the CD81 receptor and to undergo N-glycosylation
processing similar to that in mammalian cells is strong indication
that functional folding of these complex viral proteins occurs in
plant cells. Lettuce does not need to be cooked and, therefore, is
an ideal candidate edible crop for oral vaccine development.
Also, both stable chloroplast transformation and transient
expression technologies are well established in lettuce (Ruhlman
et al., 2007; Lai et al.,2012; Kwon and Daniell, 2015; Ma et al.,
2015; Clarke et al. unpublished results; Chen et al., 2016;
current study). Chen and co-workers have recently demonstrated
that a cold chain-independent plant-made viral protein 1 (VP1)
subunit oral booster vaccine produced in tobacco and lettuce
using chloroplast genetic engineering is a promising candidate
for future oral booster polio vaccine development (Chen et al.,
2016). Animal trials have shown that the oral booster VP1
conferred immunity against different poliovirus serotypes. Future
clinical trials are hoped to provide further information about the
efficacy of this oral booster polio vaccine in humans (Chen et al.,
2016). However, to date, there are only few reports on oral
vaccines produced in lettuce and the functionality of oral
antigens in animal trials.
Analysis of the HCV antigen immunogenicity in mice showed
that immunization performed by oral feeding only resulted in a
relatively weak anti-HCV IgM response. Interestingly, while anti-
HCV IgG Abs were readily detectable on day 28 in mice primed
and boosted by injection, this response was obtained on day 42
when the boost was performed by lettuce feeding. This obser-
vation suggests a delayed activation of systemic immunity,
possibly as a consequence of oral tolerance acquisition. This
hypothesis is also supported by the results showing the absence
of anti-HCV IgG Abs from the sera of mice immunized exclusively
by feeding with either E1E2 or E1E2ΔN6 dimers.
The ability of plant-derived vaccines to induce both systemic
and mucosal immune response has been previously shown (Kong
et al., 2001; Walmsley and Arntzen, 2000); however, vaccines
delivered by injection, while effective inducers of systemic
immunity, are less efficient at inducing mucosal responses
(Walmsley and Arntzen, 2000). It is well documented that the
gut-associated lymphoid tissue (GALT) determines adaptive
immunity versus tolerance in relation to antigen structure, dosage
and duration of exposure (Mowat, 2003; Pamer, 2007). In this
respect, a significant difference regarding the faecal levels of
sIgA, a hallmark of mucosal immunity activation, was observed
between the mice groups fed with lettuce-derived E1E2 or
E1E2ΔN6 dimer. Oral immunization with E1E2ΔN6-containing
lettuce induced the highest amount of anti-HCV sIgA Abs, the
best response being detected at days 14 and 28, followed by a
slow decrease by day 42. This is in agreement with the previous
observation that some oligosaccharides attached to the E2
protein may shield potential immunogenic epitopes, and high-
lights the importance of the Asn532 N-linked glycan (N6) in this
process (Helle et al., 2007).
HCV-specific sIgA Abs were also detected in faeces extracts of
mice primed by intramuscular injection. Notably, the Abs titres
were significantly higher in the group boosted by oral feeding
compared to parenteral inoculation, indicating the importance of
the immunization protocol for a successful oral vaccination
(Czerkinsky et al., 1993; Mestecky et al., 2007). As the E1E2
dimer is the current vaccine candidate, both oral and injection
administrations of the antigen were performed with this protein.
Nevertheless, as the E1E2ΔN6 dimer induced higher sIgA titres,
when administered exclusively by feeding, it is tempting to
speculate that this de-glycosylated antigen may change the
Figure 8 IgG endpoint titres in sera of HEK293T-derived E1E2 primed
mice. 1 – intramuscular prime with E1E2 purified from HEK293T cells,
followed by two oral boosts with lettuce-E1E2; 4- prime and boost
injection with E1E2 purified from HEK293T cells; endpoint titres were
calculated as described in Figure 7.
Figure 9 sIgA endpoint titres in faeces of
immunized mice. 1 – intramuscular prime with
E1E2 purified from HEK293T cells, followed by
two oral boosts with lettuce-E1E2; 2 – three oral
administrations of lettuce-E1E2ΔN6; 3 – three oral
administrations of lettuce-E1E2; 4 – two
intramuscular administrations of E1E2 purified
from HEK293T cells; endpoint titres were
calculated as described in Figure 7.
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specificity of the antibody response, as compared to the E1E2
protein. Together, these data suggest that association of
parenteral with oral immunization may lead to the development
of both systemic and mucosal immune responses, which could
provide a more effective prophylaxis against pathogens causing
chronic diseases such as HCV.
Moreover, its successful transient expression in lettuce demon-
strates the potential of plant-made oral vaccines also in those
cases where complex protein maturation pathways are involved.
Future studies will aim at determining the optimum parameters
for oral vaccination, such as dosage, timing, immunization routes
and antigen formulation, and will also include molecular studies
on mucosal and systemic immune responses and possible
tolerance induction.
Experimental procedures
Mammalian cell lines and expression vectors
HEK239T cells (European Collection of Animal Cell Culture,
Porton Down, UK) were grown in DMEM (1x) + GlutaMAXTM-I
medium (Life Technologies, Carlsbad, USA) containing 10%
foetal bovine serum (FBS). Cloning of the full-length wt E1E2
heterodimer and of the variant containing the mutation Asn532/
Gln within the E2 polypeptide (E2ΔN6) into the mammalian
expression vector phCMVdeltaC was described previously by
Helle et al. (2007). The resulting expression vectors were further
denoted phCMVdeltaC-E1E2 and phCMVdeltaC-E1E2ΔN6,
respectively. The HCV genotype is 1a (isolate H77).
Expression of the E1E2 heterodimer in HEK cells and
purification
HEK293T cells were amplified in T75 tissue culture flasks before
being transferred to 1700 cm2 ribbed surface roller bottles
(Greiner Bio One, Austria) at a density of ~2.5 9 107 cells/bottle,
then further grown in a Roll-In CO2 Control incubator
(Wheaton). Cells were transfected with phCMVdeltaC-E1E2 at
day 3 postseeding in the presence of 1 lg/mL polyethylenimine
(PEI). Cells were harvested at day 3 post-transfection and lysed in
phosphate-buffered saline (PBS) containing 1% Triton X-100 and
a mixture of protease inhibitors (Santa Cruz Biotechnology,
Dallas, USA). Lysates were centrifuged for 10 min at 10 000 g
and the total protein content was determined in clear super-
natants using the bicinchoninic acid (BCA) method (Pierce). The
supernatants were incubated overnight with Galanthus nivalis
(GNA)-conjugated Sepharose (Sigma-Aldrich, St.Louis, USA) and
bound high-mannose glycoproteins were eluted in the presence
of 2 M methyl a-D-mannopyranoside (Sigma-Aldrich, St.Louis,
USA). The eluates were extensively dialysed against PBS and
concentrated on Amicon50x columns (Merck Millipore, Ireland).
Serial dilutions of samples were analysed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot with anti-E2 Abs 3/11 (kindly provided by J.A.
McKeating, University of Birmingham, UK).
Construction of E1E2 and E1E2ΔN6 plant expression
vectors
The E1E2 coding region was excised from the phCMVdeltaC-
E1E2 and phCMVdeltaC-E1E2ΔN6 vectors and inserted into the
plant transient expression vector pEAQ-HT-DEST1 (Sainsbury
et al., 2009) using a Gateway cloning system provided by Life
Technologies (BP&LR Clonase II kit, donor vector pDONRTM/Zeo,
Invitrogen Carlsbad, USA). The Gateway cloning BP and LR
reactions (Karimi et al., 2002) were conducted according to the
manufacturer’s protocol. The GFP reporter gene and the HCV
E1E2 and E1E2ΔN6 encoding genes flanked by attB1 and attB2
recombination sites generated by PCR reaction (attB1_HCV:
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGAATTCCGACCT
CATGGG/attB2_HCV: GGGGACCACTTTGTACAAGAAAGCTGGG
TTTACTCCGCTTGGGATATGA) were introduced into the donor
vector pDONRTM/Zeo via BP recombination reaction and thereafter
transformed into One Shot OmniMAXTM 2-T1R Chemically Com-
petent E. coli. The generated entry clones from BP reaction were
confirmed by sequencing and subsequently introduced into the
destination vector pEAQ-HT-DEST1 (kindly provided by Prof.
Lomonossoff’s laboratory and described by Sainsbury et al.,
2009) by LR reaction generating pEAQ-HT-DEST1/GFP, pEAQ-
HT-DEST1/E1E2 and pEAQ-HT-DEST1/E1E2ΔN6 transient expres-
sion vectors.
Agrobacterium-mediated transient expression in lettuce
The plant expression vectors pEAQ-HT-DEST1/GFP, pEAQ-HT-
DEST1/E1E2 and pEAQ-HT-DEST1/E1E2ΔN6 were introduced into
the ElectroMAXTM Agrobacterium tumefaciens LBA4404 cells
(Invitrogen Carlsbad, USA) by electroporation using BTX ECM
630 electroporator (BTX-Division of Harvard Apparatus, USA,
2.0 kV, 200 Ω and 25 lF as described by Clarke et al., 2008).
The Agrobacterium LBA4404 harbouring the expression vectors
were cultured on LB medium supplemented with 50 mg/L
kanamycin and incubated at 28 °C for 72 h. The transformed
clones were verified and confirmed by colony PCR using the gene-
specific-attB1/attB2 primer pair shown above (attB1_HCV/
attB2_HCV).
For agroinfiltration, the Agrobacterium harbouring pEAQ-HT-
DEST1/GFP, pEAQ-HT-DEST1/HCVE1E2 and pEAQ-HT-DEST1/
HCVE1E2ΔN6 plasmids were cultured and prepared for the
agorinfiltration basically as described by Sainsbury et al. (2009)
and Saxena et al. (2016) with minor modifications including the
establishment and optimization of our in-house vacuum-based
agroinfiltration protocol. Four-six-week old lettuce plants grown
in the growth chamber under a photoperiod of 16-h light and 8-h
dark with a temperature of 22 °C were subjected to agroinfil-
tration, using a 2-mL syringe without needle on the underside of
the leaf, basically as described by Sainsbury et al. (2009). After
the agroinfiltration, the lettuce plants were further grown in the
confined S2 safety level growth chamber with the same light and
temperature conditions.
Agroinfiltration at a large scale (>30 plants) was carried out by
an in-house assembled vacuum system. Due to the different plant
characteristics, the different vacuum conditions were developed
and optimized for Nicotiana benthamiana and lettuce, respec-
tively, with pressure ranged from 0.01 to 0.1 bar; for 1 and
2 min; repeating one or two times.
Quantitative analysis of E1E2 and E1E2ΔN6 expressions
in lettuce by qRT-PCR
Leaf samples harvested at different time intervals (dpi) were
submerged immediately in liquid nitrogen and total RNA was
isolated using SpectrumTM Plant Total RNA kit (Sigma-Aldrich,
St.Louis, USA). An additional clean-up to remove any trace DNA
left in the samples was performed using Ambion Turbo RNA
Purify kit (Ambion Austin, USA). The quality and concentration of
the final yielded RNA was evaluated by Bioanalyzer (Agilent
Technologies Santa Clara, USA). The cDNA was synthesized from
1.0 lg RNA using a cDNA synthesis kit (Bio-Rad, Hercules, USA).
ª 2017 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and the Association of Applied Biologists and John Wiley & Sons Ltd., 15, 1611–1621
Jihong Liu Clarke et al.1618
The qRT-PCR reactions were carried out on CFX96 real-time
system (Bio-Rad, Hercules, USA) using SsoAdvanced SYBR Green
SuperMix (Bio-Rad, Hercules, USA). A 10-ng cDNA was applied as
template into 20 lL qPCR in addition to 0.8 lM primers (HCV/
N6_F: TTCAGGCTGTCCTGAGAGGT and HCV/N6_R: CCACAA
GGTCTTGGAGGGTA). The endogenous reference genes actin
and elongation factor were used (ACT_F: AGGGCAGTGTTTCC
TAGTATTGTTG and ACT_R: CTCTTTTGGATTGTGCCTCATCT)
and EIF2 (EIF2A_F: TAGGCGAGTGGAGAAGCATT and EIF2A_R:
GTAGAAACAGCAACAGGCAAA). The qPCR thermal cycle pro-
gramme was with initial denaturing at 95 °C for 6 min followed
by 40 cycles at 95 °C for 15 s, 61 °C for 15 s and 72 °C for 45 s.
Gene expression analysis was performed using the built-in CFX
Manager (Bio-Rad, Hercules, USA). Normalized expression DDCq
was used to estimate the transcript level using the differences of
Ct (threshold cycle) value between endogenous reference genes
and target gene.
Antigen extraction from pEAQ-HT-DEST1/E1E2 and
pEAQ-HT-DEST1/E1E2ΔN6 expressing lettuce plants and
N-glycosylation analysis
Lettuce leaves were ground in liquid nitrogen. The ground
material was then homogenized in 5 volumes of extraction buffer
containing 20 mM Na2HPO4, 0.15 M NaCl, 20 mM Na ascorbate,
0.5% Triton X-100 and a protease inhibitor cocktail (Santa Cruz
Biotechnology, Dallas, USA), pH 7, for 1 h, on ice. The
homogenate was centrifuged at 1000 g, for 5 min, at 4 °C. The
supernatant was collected, and the total protein content was
determined using the BCA method. To determine the N-
glycosylation status of the viral antigens, samples were further
treated with EndoH (New England Biolab, UK) following the
protocol supplied, then subjected to SDS-PAGE and Western
blotting with either anti-E1 Abs A4 (kind gift from H.B. Greenberg,
VA Medical Center, Palo Alto, California) or anti-E2 Abs 3/11.
CD-81 pull-down assay
A recombinant large extracellular loop of human CD81 (CD81-
LEL) fused to glutathione S-transferase (GST) was adsorbed onto
glutathione–Sepharose beads (GE Healthcare), as previously
described (Helle et al., 2007). Nontransformed lettuce lysates
(negative control) or extracts containing the E1E2 and E1E2ΔN6
proteins were added to 50 lL of beads and incubated overnight
at 4 °C. The beads were washed two times with PBS containing
1% Triton X-100 then resuspended in Laemmli buffer containing
200 mM Tris-HCl (pH 6.7), 0.5% SDS, 10% glycerol and 100 mM
b-mercaptoethanol. Samples were boiled and separated by SDS-
PAGE followed by Western blotting and detection with either
anti-E1 or anti-E2 Abs. Lysates of E1E2-expressing HEK cells were
used in the experiment as positive control.
SDS-PAGE and Western blotting
Protein samples were heat-denatured in Laemmli buffer and run
on SDS-PAGE (10% polyacrylamide gels). Separated proteins
were further blotted onto nitrocellulose membranes using a
semi-dry blotter (Bio-Rad, Hercules, USA). The membranes were
blocked with 5% nonfat milk in PBS and incubated with the rat
anti-E2 3/11 Abs or the anti-E1 A4 monoclonal Abs (both diluted
at 1/2000 in 5% nonfat milk in PBS with 0.1% Tween). Goat
anti-rat-HRP and rabbit anti-mouse HRP-conjugated antibody
(Santa Cruz Biotechnology, Dallas, USA dilution 1/10 000) were
used as secondary Abs. The protein bands were visualized using
an ECL substrate (Thermo Scientific Waltham, USA). The amount
of HCV antigens was determined based on serial dilutions of
known concentrations of HEK293T-produced E1E2 dimer. The
level of expression of each of the HCV antigens was estimated at
90 ng/g leaf material.
Animals and immunization
BALB/c female mice, 6–8 weeks of age, were purchased from
Charles River Laboratories (INNOVO Ltd., Hungary) and housed
with free access to standard chow and tap water. All animal care
was in accordance with standards set forth in the Council
Directive 86/609/EEC, and the mice experimentation was
approved by the Internal Ethics Committee of the “Cantacuzino”
Institute. The mice were randomly assigned in five groups: four
groups of five animals including nonimmunized mice and one
group of seven animals (Table 2).
Three of the groups received the antigens three times at 1-
week intervals, either by the oral route only or by parenteral
priming followed by oral antigen boosting. Oral immunization
consisted in individual feeding of mice, overnight, with a pellet
obtained by mixing 10 g lettuce powder (containing ~900 ng of
either E1E2 or E1E2ΔN6 antigens) obtained by liquid nitrogen
pulverization, with ~2 g standard chow powder. Priming was
done with 50 lL PBS suspension containing 5 lg of HEK293T
cells-produced E1E2 antigen, given by intramuscular injection.
One group received two injections with 2.5 lg of HEK293T cells-
produced E1E2 antigen at a 14 day interval, at the same volume
per dose (Table 2).
Blood samples were collected by retro-orbital bleeding prior
to priming, at day 14 before the third oral antigen boost and
at days 28 and 42 postimmunization. Following clotting,
samples were centrifuged at 14 000 g for 10 min at room
temperature and the resulting sera were stored at 80 °C until
further analysis. Faecal pellets were also collected from each
mouse, at the same intervals, and diluted in PBS containing
0.02% sodium azide (Sigma-Aldrich, St.Louis, USA), to a final
concentration of 10 mg dry matter/mL of PBS. Diluted faecal
pellets were homogenized and centrifuged at 14 000 g for
10 min. Clear supernatants were collected and stored at
80 °C until assayed.
Enzyme-linked immunosorbent assay (ELISA)
Flat-bottom 384-well MediSorp plates (Sigma-Aldrich, St.Louis,
USA) were coated with 0.24 lg/mL of HEK293T cell-produced
E1E2 antigen, in PBS, overnight at 4 °C. The plates were washed
five times with PBS containing 0.05% Tween 20 (Sigma-Aldrich,
St.Louis, USA), blocked with PBS containing 5% nonfat dry milk
(Bio-Rad, Hercules, USA), for 1 h at room temperature and
further washed 5 times with PBS containing 0.05% Tween 20.
Serum samples were twofold serially diluted (1:200–1:6400) in
PBS containing 5% nonfat dry milk then added to the antigen
coated plates (40 lL/well) and incubated for 2 h at room
temperature. Faecal suspensions (40 lL/well) were twofold seri-
ally diluted (1 : 2–1 : 8) as above. The plates were washed five
times with PBS containing 0.05% Tween 20, before incubation
with HRP-conjugated goat anti-mouse IgM/IgG/IgA adsorbed
against human immunoglobulins (Southern Biotech), diluted
6000-fold in PBS containing 5% nonfat dry milk, for 2 h at room
temperature. The faeces samples were incubated with HRP-
conjugated goat anti-mouse IgA only. The plates were washed
five times before addition of the TMB substrate (R&D Systems)
and further incubated for 20 minutes at room temperature.
Reactions were stopped with 20 lL/well of 1M H2SO4 and
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absorbance was measured at 450 nm using a Tecan Infinite
M1000 microplate reader.
Data normalization and processing
To allow normalization across ELISA plates, an internal standard
was produced by pooling all the immune sera from the same
experiment in one control sample. Three internal standards were
also produced from immune faeces suspension collected at day
14 from the E1E2/E1E2ΔN6 antigens-immunized groups and the
control group, respectively. Twelve serum and faeces serial
dilutions starting from 1/100 and 3/4, respectively, were used
as internal standard on each plate and a 4-parameter logistic
regression model was fitted to the measured values. Sample
dilutions falling within the standard range, with an estimated
error <30%, were averaged by median. Endpoint titres were
calculated as the reciprocal sample dilution that would result in
three times baseline + standard error as derived from the internal
standard curve by multiplication. All calculations were performed
in R version 3.1.1 (Team, 2014) using the calibFit 2.1.0 package
(Haaland et al., 2011).
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